-
Featured
Low-risk Incidental Prostate Cancer in Men with Bladder Cancer May Be Associated with Longer Survival
Men with bladder cancer who have low-risk prostate cancer detected incidentally by radical cystoprostatectomy may actually have a more favorable prognosis than those who do not.
-
Featured
Ultrasound Therapy Yields Promising Results for Localized Prostate Cancer
At the American Urological Association's 2019 Annual Meeting, researchers presented the findings of a study on the effects transurethral ultrasound ablation (TULSA), a novel minimally invasive procedure that can reduce prostate size and prostate-specific antigens in patients with localized prostate cancer.
-
Featured
New Target Discovered for Prostate Cancer Immunotherapy
Genitourinary pathologists at Massachusetts General Hospital are the first to demonstrate that PD-L1 expression is highly prevalent in prostate tumor-associated nerves. Such nerves may represent an important target for immunotherapy regimens.
-
Case Series: Mucinous Adenocarcinoma of the Prostatic Urethra After Brachytherapy for Prostatic Adenocarcinoma
Massachusetts General Hospital researchers present the first case series of brachytherapy-associated mucinous adenocarcinoma of the prostatic urethra, reviewing clinical and pathologic differences from its radiation-independent counterpart and concluding it's associated with lower stage and less aggressive behavior.
-
Combination of Darolutamide, ADT, and Docetaxel Improves Survival of Patients With Metastatic, Hormone-sensitive Prostate Cancer
Matthew R. Smith, MD, PhD, and colleagues present compelling evidence that survival is significantly better among patients with metastatic, hormone-sensitive prostate cancer who receive darolutamide, androgen-deprivation therapy, and docetaxel than those who receive androgen-deprivation therapy and docetaxel alone.
-
Targeted Biopsy Alone Detects Clinically Significant Cancer in Smaller Prostates
Douglas M. Dahl, MD, Chin-Lee Wu, MD, PhD, and colleagues found that in patients with smaller prostates (≤30 mL), transperineal multiparametric MRI-targeted biopsy alone does as well as the combination of targeted and conventional biopsy at detecting clinically significant cancer.
Mass General Cancer Center Contributors
-
Adam Scott Feldman, MD, MPH
Director, Combined Harvard Urologic Oncology Fellowship, Director of Research and Urologic Oncologist, Department of Urology, Massachusetts General Hospital
Recent Article
Review: Active Surveillance for Intermediate-risk Prostate Cancer
-
Chin-Lee Wu, MD, PhD
Director, Genitourinary Pathology Service, Massachusetts General Hospital and Mass General Cancer Center, Professor of Pathology, Harvard Medical School
Recent Article
Case Series: Mucinous Adenocarcinoma of the Prostatic Urethra After Brachytherapy for Prostatic Adenocarcinoma
-
Douglas Middleton Dahl, MD
Chief, Division of Urologic Oncology, Director of Robotic Surgery, Massachusetts General Hospital, Associate Professor of Surgery (Urology), Harvard Medical School
Recent Article
Genetic Signature Predicts Metastasis, Survival in Clear Cell Renal Cell Carcinoma
-
Mass General Bladder, Kidney, Penile, Prostate and Testicular Cancer Program
Physicians in the Mass General Bladder, Kidney, Penile, Prostate and Testicular Cancer Program specialize in using advanced surgical therapies and minimally invasive procedures to treat male and female genitourinary cancers.
